eczema Archives -

10 Tips for Digital Asset Management Success

DiME digital measure is nocturnal scratch for atopic dermatitis

Nicole Raleigh atopic dermatitis, dermatology, digital endpoint, digital health, Digital Medicine Society (DiMe), eczema, Medical, nocturnal scratch, product development 0 Comment

The Digital Medicine Society (DiME) is today releasing a new set of open-access resources to advance the use

DiME digital measure is nocturnal scratch for atopic dermatitis

https://pharmaphorum.com/digital/dime-digital-measure-is-nocturnal-scratch-for-atopic-dermatitis/

Patients/ Views & Analysis/ Views and analysis

Patient Insights: Eczema

George Underwood eczema, patient insights 0 Comment

Ellen Scheib has had eczema for over twenty years, and though drugs have helped her manage the condition

Patient Insights: Eczema

https://pharmaphorum.com/views-analysis-patients/patient-insights-eczema/

News/ News/ R&D

Incyte gets much-needed boost as eczema cream trial hits target

Richard Staines atopic dermatitis, eczema, Incyte, R&D 0 Comment

US biotech Incyte has announced positive topline results from a phase 3 trial of its ruxolitinib eczema cream

Incyte gets much-needed boost as eczema cream trial hits target

https://pharmaphorum.com/news/incyte-gets-much-needed-boost-as-eczema-cream-trial-hits-target/

Market Access/ News/ News

Sanofi’s Dupixent funded in Wales and Scotland for adolescents with eczema

Richard Staines eczema, market access, Sanofi 0 Comment

Sanofi’s Dupixent (dupilumab) has been cleared for NHS funding in Wales and Scotland in adolescents with severe eczema,

Sanofi’s Dupixent funded in Wales and Scotland for adolescents with eczema

https://pharmaphorum.com/news/sanofis-dupixent-funded-in-wales-and-scotland-for-adolescents-with-eczema/

News

Novartis’ $100m bet on eczema drug fails as MOR106 development ends

George Underwood atopic dermatitis, eczema, Galapagos, MorphoSys, Novatis 0 Comment

Galapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in

Novartis’ $100m bet on eczema drug fails as MOR106 development ends

https://pharmaphorum.com/news/novartis-100m-bet-on-eczema-drug-fails-as-mor106-development-ends/

Market Access/ News/ News

Sanofi’s eczema drug gets EU approval to treat adolescents

George Underwood atopic dermatitis, Dupixent, eczema, Sanofi 0 Comment

The European Commission (EC) has extended the marketing authorisation for Sanofi and Regeneron’s eczema drug Dupixent (dupilumab) to

Sanofi’s eczema drug gets EU approval to treat adolescents

https://pharmaphorum.com/news/sanofi-eczema-drug-gets-eu-approval-adolescents/

Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Almirall gets in on the eczema action

Richard Staines Almirall, atomic dermatitis, Dupixent, eczema, LEO Pharma, Sanofi 0 Comment

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall

Almirall gets in on the eczema action

https://pharmaphorum.com/views-analysis-market-access/almirall-gets-in-on-the-eczema-action/

Patients/ Views & Analysis/ Views and analysis

Patient Insights: Severe psoriasis & eczema

George Underwood eczema, Howard Chang, Inspire, patient insights, psoriasis, severe psoriasis 0 Comment

Howard Chang has lived with severe psoriasis and atopic dermatitis for almost 40 years since childhood. Now a

Patient Insights: Severe psoriasis & eczema

https://pharmaphorum.com/views-analysis-patients/patient-insights-severe-psoriasis-eczema/

News

FDA approves Sanofi/Regeneron’s Dupixent in asthma

Richard Staines asthma, eczema, Regeneron, Sanofi 0 Comment

The US regulator has approved Sanofi/Regeneron’s Dupixent (dupilumab) in a new asthma indication, a key step in the

FDA approves Sanofi/Regeneron’s Dupixent in asthma

https://pharmaphorum.com/news/fda-approves-sanofi-regenerons-dupixent-in-asthma/

Trending

eczema

Login